In respect of the above mechanism, it was concluded that MCL could be viewed as an effective agent against a series of inflammation-related diseases where the NF-κB signaling pathway plays a key part in, including IBD, colitis, RA, sepsis, and tuberculosis. This evidence concerns the gene NFKB1 and colitis.